Jar­diance sup­ports 

Pharmacy Daily - - NEWS -

d, lat­est data on the use of Boehringer In­gel­heim’s Jar­diance (em­pagliflozin) pre­sented at this year’s meet­ing of the Euro­pean As­so­ci­a­tion for the Study of Di­a­betes (EASD) demon­strated lower risk of car­dio­vas­cu­lar death com­pared with placebo re­gard­less of back­ground met­formin or sulpho­ny­lurea use.

C>/C< , Z to read the re­search.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.